Market Flux Event
Recursion Pharmaceuticals Stock Rises 4% After Reaching FDA Alignment on REC-4881 Phase 3 Trial Design
Read this in the Market Flux appRecursion Pharmaceuticals closed at $2.83 on November 18, up 3.86%, after the AI-enabled clinical-stage drug company announced it had reached alignment with the FDA on the Phase 3 trial design for REC-4881, its investigational MEK1/2 inhibitor for familial adenomatous polyposis.
REC-4881 is a potential first-in-class oral therapy that has already received FDA Orphan Drug and Fast Track designations. It targets both the Wnt/beta-catenin initiation and MAPK evolution pathways, a mechanism identified through Recursion's AI drug discovery platform. The company had previously reported positive Phase 2 results from its ongoing TUPELO Phase 1b/2 trial, with data covering 26 safety evaluable patients across the Phase 1b and Phase 2 portions.
Recursion has indicated it anticipates initiating a registrational trial in the second half of 2027, pending the FDA alignment it has now secured. Investors are watching for further regulatory and design details to be disclosed as the company moves toward that milestone.
© AI-generated summary is provided by Market Flux
Sources
- Seeking AlphaAlpha Tau Medical: The Rubber Meets The Road In H1 2027
- InvestingForm 8K WAVE LIFE SCIENCES For: 18 November
- NasdaqStock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design
- Proactive_X$ACW Small Caps Watch: Actinogen reports Alzheimer’s trial results, Lumos expands into Portugal @ActinogenMed #ACW #ATGGF #ASX #ASXNews